Supriya Lifescience Limited has informed the Exchange regarding Change in Director(s) of the company.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Supriya Lifescience has informed the exchange that the five-year tenure of two Independent Directors, Mr. Dinesh Navnitlal Modi (DIN: 00004556) and Mr. Dileep Kumar Jain (DIN: 00380311), ended on March 24, 2026. The exit is due to completion of their statutory term, not resignation or removal. The Board has already reconstituted its Audit, Nomination & Remuneration, and Stakeholders' Relationship Committees at its February 9, 2026 meeting to fill the resulting vacancies. No new appointments to replace them have been disclosed in this filing. The company acknowledged the contributions of both directors during their tenure.
This is a routine, regulatory-driven governance change rather than a negative event. Two independent directors stepping down simultaneously means the company will need to appoint new independent directors soon to maintain SEBI's board composition requirements. Short-term impact on the stock is likely neutral, though investors should watch for announcements on replacement appointments.